| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.8 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.8 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.8 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.007 | 0.8 |